PMID- 28598698
OWN - NLM
STAT- MEDLINE
DCOM- 20180622
LR  - 20210924
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Linking)
VI  - 17
IP  - 8
DP  - 2017 Aug
TI  - Beyond serotonin: newer antidepressants in the future.
PG  - 777-790
LID - 10.1080/14737175.2017.1341310 [doi]
AB  - There are numerous antidepressants for the treatment of major depressive disorder 
      (MDD) on the market. However, inadequate treatment response, therapeutic lag 
      between drug administration and the onset of clinical improvement, and 
      safety/tolerability issues with the use of contemporary antidepressants have 
      accelerated the search for newer antidepressants with novel mechanisms of action. 
      Areas covered: The authors review novel antidepressants with rapid efficacy for 
      diverse MDD symptoms and have fewer adverse effects (AEs). Mechanisms of action 
      for novel therapeutic molecules are through glutamatergic, opiate, cholinergic 
      receptors and neuroplasticity. We enumerate results from human trials with novel 
      agents in all phases, highlighting proximity to approval and therapeutic 
      potential based on quality of evidence. Expert commentary: There is a huge unmet 
      need to diversify conventional antidepressant targets. Glutamatergic and opiate 
      agents may be most promising among newer therapeutic agents. It is also important 
      to develop advanced but flexible synergistic treatment strategies with newer 
      therapeutic agents that are usable in routine clinical practice. This would 
      include combining newer molecules with existing antidepressants and using 
      molecules that target specific symptom dimensions of MDD. These strategies would 
      lead to a systematic approach to tackle treatment resistant depression (TRD) and 
      treatment of residual symptoms in partially remitted MDD.
FAU - Rakesh, Gopalkumar
AU  - Rakesh G
AD  - a Department of Psychiatry and Behavioral Sciences , Duke University Medical 
      Center , Durham , NC , USA.
FAU - Pae, Chi-Un
AU  - Pae CU
AD  - a Department of Psychiatry and Behavioral Sciences , Duke University Medical 
      Center , Durham , NC , USA.
AD  - b Department of Psychiatry , The Catholic University of Korea College of Medicine 
      , Seoul , Republic of Korea.
FAU - Masand, Prakash S
AU  - Masand PS
AD  - c Academic Medicine Education Institute , Duke-NUS Medical School , Singapore , 
      Singapore.
AD  - d Global Medical Education , New York , NY , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170619
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Antidepressive Agents/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Depressive Disorder, Major/*drug therapy
MH  - Drug Discovery/*trends
MH  - Drug Evaluation
MH  - Drug Therapy, Combination
MH  - Humans
MH  - *Molecular Targeted Therapy
OTO - NOTNLM
OT  - Antidepressants
OT  - beyond
OT  - future
OT  - glutamate
OT  - neuroplasticity
OT  - serotonin
EDAT- 2017/06/10 06:00
MHDA- 2018/06/23 06:00
CRDT- 2017/06/10 06:00
PHST- 2017/06/10 06:00 [pubmed]
PHST- 2018/06/23 06:00 [medline]
PHST- 2017/06/10 06:00 [entrez]
AID - 10.1080/14737175.2017.1341310 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2017 Aug;17(8):777-790. doi: 10.1080/14737175.2017.1341310. 
      Epub 2017 Jun 19.